Investigating the Role of YKL40 in Prostate Cancer

This project unraveled the biomarker and therapeutic potential of a clinically relevant protein molecule called YKL40. YKL40 can be easily detected in the patient's blood and can be targeted therapeutically in patients who have increased levels of YKL40. This project showed, for the first time, that advanced prostate cancer patients show higher levels of YKL40 and the growth of prostate cancer can be slowed down by reducing the levels of YKL40. This project led to an early-career grant and a peer-reviewed publication in a reputed journal, Endocrine related cancer.